LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Closed

SectorHealthcare

18.62 -3.37

Buy Sell

Overview

Share price change

24h

Current

Min

18.42

Max

19.3

Key metrics
By Trading Economics
Income	102K -128M
EPS	-0.69
Employees	503
EBITDA	-9.8M -135M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+81.36% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	159M 3.1B
Previous open	21.99
Previous close	18.62

News Sentiment

By Acuity

50%

155 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.355 / 16.44 Support & Resistance

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 May 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 May 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 May 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 May 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 May 2026, 16:02 UTC

Earnings

Major Market Movers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 May 2026, 14:55 UTC

Major Market Movers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 May 2026, 14:43 UTC

Major Market Movers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 May 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 May 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 May 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 May 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 May 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 May 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 May 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 May 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 May 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 May 2026, 16:24 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 May 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 May 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 May 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 May 2026, 15:20 UTC

Earnings

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 May 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

81.36% upside

12 Months Forecast

Average 35.91 USD 81.36%

High 42 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.355 / 16.44Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

155 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.